Skip to content

US researchers estimate HIV treatment will work for 24 years and cost £200k

New risk factors for severe liver toxicity identified in largest ever clinical trial-based analysis

Lowering the threshold — Is there a case for re-evaluating eligibility criteria for ART?

High risk of AIDS or death in HIV-positive individuals in South Africa ineligible for antiretrovirals

Two-drug maintenance with tenofovir-efavirenz less effective than triple therapy

Immunologically discordant response to HIV therapy associated with increased risk of disease progression

CXCR4, dual or mixed tropic HIV does not reduce response to HAART

Boosted fosamprenavir and atazanavir show comparable potency, tolerability in treatment-naive

Trizivir non-inferior to unboosted atazanavir in treatment-naive